Consequences of chronic anemia in the older person

Blood Disorders in the Elderly

Volumn , Issue , 2007, Pages 192-202

  Balducci, Lodovico ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78349232843     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545238.016     Document Type: Chapter

References (102)

1. Balducci L, Aapro M. Anemia and aging or anemia of aging. Cancer Treat Res 2007; in press.
2. Mor V. The compression of morbidity hypothesis: a review of research and prospects for the future. J Am Geriatr Soc 2005; 53 (9 Suppl): S308-S309.
3. Fries GF. Frailty, heart disease, and stroke: the compression of morbidity paradigm. Am J Prev Med 2005; 29 (5 Suppl 1): 164-8.
4. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104: 2263-8.
5. Patel KV, Harris TB, Faulhaber M, et al. Racial variation in the relationship of anemia with mortality and mobility disability among older adults. Blood 2007; 109: 4663-70.
6. Chaves PH, Ashar B, Guralnik JM, Fried LP. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated? J Am Geriatr Soc 2002; 50: 1257-64.
7. Chaves PH, Semba RD, Leng SX, et al. Impact of anemia and cardiovascular diseases on frailty status of community dwelling women. The Women’s Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci 2005; 60: 729-35.
8. Penninx BW, Pahor M, Cesari M, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 2004; 52: 719-24.
9. Cesari M, Penninx BW, Lauretani F, et al. Hemoglobin levels and skeletal muscle: results from the In CHIANTI study. J Gerontol A Biol Sci Med Sci 2004; 59: 238-41.
10. Ania BJ, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ 3rd. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc 1997; 45: 825-31.
11. Ania BJ, Suman VJ, Fairbanks VF, et al. Prevalence of anemia in medical practice: community versus referral patients. Mayo Clin Proc 1994; 69: 730-5.
12. Inelmen EM, Alessio MD, Gatto MRA, et al. Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people at home: some results of an Italian multicentric study. Aging Clin Exp Res 1994; 6: 81-9.
13. Yamada M, Wong FL, Suzuki G, et al. Longitudinal trends of hemoglobin levels in a Japanese population: RERF’s Adult Health Study subjects. Eur J Haematol 2003; 70: 129-35.
14. Nilsson-Ehle H, Jagenburg R, Landahl S, et al. Blood hemoglobin declines in the elderly: implications for reference intervals for age 70 to 88. Eur J Haematol 2000; 65: 297-305.
15. Artz AS, Fergusson D, Drinka PJ, et al. Prevalence of anemia in skilled-nursing home residents. Arch Gerontol Geriatr 2004; 39: 201-6.
16. Kalchataler T, Tan ME. Anemia in institutionalized elderly patients. J Am Geriatr Soc 1980; 28: 108-13.
17. Ania Lafuente BJ, Fernandez-Burriel Tercero M, Suarez Almenara JL, et al. [Anemia and functional incapacity at admission to a geriatric home.] An Med Interna 2001; 18: 9-12.
18. Duthie EH. Physiology of aging: relevance to symptom perception and treatment tolerance. In Balducci L, Lyman GH, Ershler WB, Extermann M, eds, Comprehensive Geriatric Oncology, 2nd edn (London: Taylor and Francis, 2004), 207-22.
19. Ble A, Fink J, Woodman R, et al. Renal function, erythropoietin and anemia of older persons: the In CHIANTI study. Arch Intern Med 2005; 165: 2222-7.
20. Ferrucci L, Guralnik JM, Woodman RC, et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 2005; 118: 1288.
21. Choi JW. Serum-soluble transferrin receptor concentrations in Helicobacter pylori-associated irondeficiency anemia. Ann Hematol 2006; 85: 735-7.
22. Lin L, Valore EV, Nemeth D, et al. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 2007; 110: 2182-9.
23. Sipponen P, Laxen F, Huotari K, et al. Prevalence of low vitamin B12 and high homocysteine in serum of an elderly male population: association with atrophic gastritis and Helicobacter pylori infection. Scand J Gastroenterol 2003; 38: 1209-16.
24. Selhub J, Jacques PF, Roenberg IH, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999; 131: 331-9.
25. Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. Blood 2005; 105: 2294-9.
26. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23.
27. Goodnough LT. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol 2007; 35 (4 Suppl 1): 167-72.
28. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapyrelated anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-7.
29. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 2606-17.
30. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 26: 1027-32.
31. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24: 4708-13.
32. Ferrucci L, Maggio M, Brandinelli S, et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006; 166: 1380-8.
33. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-65.
34. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25: 1908-15.
35. Izaks GJ, Westendorp RGJ, Knook DL. The definition of anemia in older persons. JAMA 1999; 281: 1714-19.
36. Kikuchi M, Inagaki T, Shinagawa N. Five-year survival of older people with anemia: variation with hemoglobin concentration. J Am Geriatr Soc 2001; 49: 1226-8.
37. Zakai NA, Katz R, Hirsch C, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 2005; 165: 2214-20.
38. Penninx BW, Pahor M, Woodman RC, et al. Anemia in old age is associated with increased mortality and hospitalization. J Gerontol Med Sci 2006; 61: 474-9.
39. Culleton BF, Manns BJ, Zhang J, et al. Impact of anemia on hospitalization and mortality in older adults. Blood 2006; 107: 3841-6.
40. Walston A, Headley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology. Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 2006; 54: 991-1001.
41. Luciani A, Balducci L, Extermann M, et al. Fatigue may be a cause of functional dependence in older cancer patients. Crit Rev Oncol Hematol 2007; in press.
42. Maraldi C, Ble A, Zuliani G, et al. Association between anemia and physical disability in older patients: role of comorbidity. Aging Clin Exp Res 2006; 18: 485-92.
43. Maraldi C, Volpato S, Cesari L, et al. Anemia and recovery from disability in activities of daily living in hospitalized older persons. J Am Geriatr Soc 2006; 54: 632-6.
44. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-timesweekly dosing. J Clin Oncol 2001; 19: 2875-82.
45. Littlewood TJ, Bajett E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.
46. Crawford J. Erythropoiesis-stimulating protein support and survival. Oncology 2006; 20 (8 Suppl 6): 39-43.
47. Extermann M, Chen A, Cantor AB, et al. Predictors of tolerance from chemotherapy in older patients: a prospective pilot study. Eur J Cancer 2002; 38: 1466-73.
48. Schrijvers D, Highley M, DeBruyn E, Van Oosterom AT, Vermorken JB. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 1999; 10: 147-53.
49. Ratain MJ, Schilsky RL, Choi KE, et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 1989; 45: 226-33.
50. Silber JH, Fridman M, Di Paola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early stage breast cancer therapy. J Clin Oncol 1998; 16: 2392-400.
51. Wolff D, Culakova E, Poniewierski MS, et al. Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. J Support Oncol 2005; 3 (6 Suppl 4): 24-5.
52. Joosten E, Lemiengre J, Nelis T, et al. Is anaemia a risk factor for delirium in acute geriatric population? Gerontology 2006; 52: 382-5.
53. Marcantonio ER, Goldman I, Oray EJ, et al. The association of intraoperative factors with the development of postoperative delirium. Am J Med 1998; 105: 380-4.
54. Marks R, Allegrante JP, Ronald MacKenzie C, Lane JM. Hip fractures among the elderly: causes, consequences and control. Ageing Res Rev 2003; 2: 57-93.
55. Halm EA, Wang JJ, Boockvar K, et al. The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture. J Orthop Trauma 2004; 18: 369-74.
56. Gruson KI, Aharonoff GB, Egol KA, Zuckerman JD, Koval KJ. The relationship between admission hemoglobin level and outcome after hip fracture. J Orthop Trauma 2002; 16: 39-44.
57. Lawrence VA, Silverstein JH, Cornell JE, Pederson T, Noveck H, Carson JL. Higher Hb level is associated with better early functional recovery after hip fracture repair. Transfusion 2003; 43: 1717-22.
58. Hagino T, Sato E, Tonotsuka H, Ochiai S, Tokai M, Hamada Y. Prediction of ambulation prognosis in the elderly after hip fracture. Int Orthop 2006; 30: 315-19.
59. Su H, Aharonoff GB, Zuckerman JD, Egol KA, Koval KJ. The relation between discharge hemoglobin and outcome after hip fracture. Am J Orthop 2004; 33: 576-80.
60. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42: 812-18.
61. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a metaanalysis. J Trauma 2003; 54: 908-14.
62. Carson JL, Altman DG, Duff A, et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion 1999; 39: 694-700.
63. Maraldi C, Volpato S, Cesari M, et al. Anemia, physical disability and survival in older patients with heart failure. J Card Fail 2006; 12: 533-9.
64. Lewis BS, Karkabi B, Jaffe R, et al. Anemia and heart failure: statement of the problem. Nephrol Dial Transplant, 2005; 20 (Suppl 7): 3-6.
65. Phillips S, Olimann H, Schink T, et al. The impact of anaemia and kidney function in congestive heart failure and preserved systolic function. Nephrol Dial Transplant 2005; 20: 915-19.
66. Elabassi W, Fraser M, Williams K, et al. Prevalence and clinical complications of anemia in congestive heart failure patients followed at a specialized heart function clinic. Congest Heart Fail 2006; 12: 258-64.
67. Vasu S, Kelly P, Lawson WE. Anemia in heart failure: a concise review. Clin Cardiol 2005; 28: 454-8.
68. Silverberg DS, Wexler D, Iaina A. The role of anemia in congestive heart failure and chronic kidney insufficiency: the cardio renal anemia syndrome. Perspect Biol Med 2004; 47: 575-89.
69. Brucks S, Little WC, Chao T, et al. Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol 2004; 93: 1055-7.
70. Silverberg DS, Wexler D, Iaina A, et al. Anemia, chronic renal disease and congestive heart failure: the cardio renal anemia syndrome. The need for cooperation between cardiologists and nephrologists. Int Urol Nephrol 2006; 38: 295-310.
71. Felker GM, Adams KF, Jr, Gattis WA, O’Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004; 44: 959-66.
72. van der Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyllysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005; 112: 1743-7.
73. Wang AY, Yu AW, Lam CW, et al. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. Am J Kidney Dis 2002; 39: 600-8.
74. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 2005; 149: 391-401.
75. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003; 41: 1933-9.
76. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am J Med 2003; 114: 112-19.
77. O’Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006; 113: 986-94.
78. Kalra PR, Bolger AP, Francis DP, et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003; 91: 888-91.
79. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005; 112: 1121-7.
80. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44: 63-7.
81. Masuda S, Nagao M, Sasaki R. Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 1999; 70: 1-6.
82. Sasaki R, Masuda S, Nagao M. Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem 2000; 64: 1775-93.
83. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100: 4802-6.
84. Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116: 393-402.
85. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111: 2042-9.
86. Nikolsky E, Aymong ED, Halkin A, et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 2004; 44: 547-53.
87. Nikolsky E, Mehran R, Aymong ED, et al. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. Am J Cardiol 2004; 94: 1023-7.
88. Reinecke H, Trey T, Wellmann J, et al. Haemoglobinrelated mortality in patients undergoing percutaneous coronary interventions. Eur Heart J 2003; 24: 2142-50.
89. McKechnie RS, Smith D, Montoye C, et al. Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation 2004; 110: 271-7.
90. Lee PC, Kini AS, Ahsan C, Fisher E, Sharma SK. Anemia is an independent predictor of mortality after percutaneous coronary intervention. J Am Coll Cardiol 2004; 44: 541-6.
91. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005; 45: 1397-405.
92. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-9.
93. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555-62.
94. Yang X, Alexander KP, Chen AY, et al. The implications of blood transfusions for patients with non-STsegment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005; 46: 1490-5.
95. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345: 1230-6.
96. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999; 33: 1122-30.
97. Atti AR, Palmer K, Volpato S, et al. Anemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging 2006; 27: 278-84.
98. Zamboni V, Cesari M, Zuccala G, et al. Anemia and cognitive performance in hospitalized older patients: results from the GIFA study. Int J Geriatr Psychiatry 2006; 21: 529-34.
99. Chaves PH, Carlson MC, Ferrucci L, et al. Association between mild anemia and executive function impairment in community dwelling older women: the Women’s Health and Aging Study II. J Am Geriatr Soc 2006; 54: 1429-35.
100. Penninx BW, Pluijm SM, Lips P, et al. Late-life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc 2005; 53: 2106-11.
101. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98.
102. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007; 11: 1-220.